These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 33367981)
41. Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes. Mirabelli M; Chiefari E; Tocci V; Caroleo P; Giuliano S; Greco E; Luque RM; Puccio L; Foti DP; Aversa A; Brunetti A J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801192 [TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China. Feng Z; Tong WK; Zhang X; Tang Z Front Pharmacol; 2023; 14():1226778. PubMed ID: 37621313 [No Abstract] [Full Text] [Related]
43. Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase. Seijas-Amigo J; Salgado-Barreira Á; Castelo-Dominguez R; Pérez-Álvarez MT; Ponce-Piñón B; Fernández-Silva M; Rodríguez-Barreiro M; Pereira-Pía M; Iglesias-Moreno JM; Gago-García M; Montáns-García R; Fernandez-Perez A; FragaGayoso D; Fernandez-Montenegro M; Riveiro-Barciela B; Rilla-Villar N; Cordero A; RodríguezMañero M; González-Juanatey JR Prim Care Diabetes; 2023 Aug; 17(4):366-372. PubMed ID: 37230813 [TBL] [Abstract][Full Text] [Related]
44. Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain. Garcia de Lucas MD; Miramontes-González JP; Avilés-Bueno B; Jiménez-Millán AI; Rivas-Ruiz F; Pérez-Belmonte LM Front Endocrinol (Lausanne); 2022; 13():995646. PubMed ID: 36187123 [TBL] [Abstract][Full Text] [Related]
45. Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events. He L; Li Q; Yang Y; Li J; Luo W; Huang Y; Zhong X Front Pharmacol; 2024; 15():1416985. PubMed ID: 39040467 [No Abstract] [Full Text] [Related]
46. Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study. Lingvay I; Kirk AR; Lophaven S; Wolden ML; Shubrook JH Diabetes Ther; 2021 Mar; 12(3):879-896. PubMed ID: 33594582 [TBL] [Abstract][Full Text] [Related]
47. Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study. Roy Chowdhury S; Sadouki F; Collins E; Keen F; Bhagi R; Lim YSJ; Cozma SL; Bain SC Diabetes Ther; 2024 Apr; 15(4):869-881. PubMed ID: 38427165 [TBL] [Abstract][Full Text] [Related]
48. Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States. Wilkinson L; Hunt B; Johansen P; Iyer NN; Dang-Tan T; Pollock RF Diabetes Ther; 2018 Jun; 9(3):951-961. PubMed ID: 29557057 [TBL] [Abstract][Full Text] [Related]
49. Comparison of Effects of Injectable Semaglutide and Dulaglutide on Oxidative Stress and Glucose Variability in Patients with Type 2 Diabetes Mellitus: A Prospective Preliminary Study. Omachi T; Ohara M; Fujikawa T; Kohata Y; Sugita H; Irie S; Terasaki M; Mori Y; Fukui T; Yamagishi SI Diabetes Ther; 2024 Jan; 15(1):111-126. PubMed ID: 37880502 [TBL] [Abstract][Full Text] [Related]
50. The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes. Rasmussen MF Diabetol Int; 2020 Apr; 11(2):76-86. PubMed ID: 32206477 [TBL] [Abstract][Full Text] [Related]
51. The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain. Vidal J; Malkin SJP; Hunt B; Martín V; Hallén N; Javier Ortega F Diabetes Ther; 2020 Feb; 11(2):509-521. PubMed ID: 31925724 [TBL] [Abstract][Full Text] [Related]
52. Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes in Treatment Intensification: A Retrospective Observational Single-Center Study. Yamada H; Yoshida M; Suzuki D; Funazaki S; Nagashima S; Masahiko K; Kiyoshi O; Hara K Diabetes Ther; 2022 Oct; 13(10):1779-1788. PubMed ID: 36006593 [TBL] [Abstract][Full Text] [Related]
53. Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study. Ghosal S; Sinha B Clin Diabetes Endocrinol; 2018; 4():11. PubMed ID: 29760945 [TBL] [Abstract][Full Text] [Related]
54. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Luo Q; Wei R; Cai Y; Zhao Q; Liu Y; Liu WJ Front Med (Lausanne); 2022; 9():793203. PubMed ID: 35280867 [TBL] [Abstract][Full Text] [Related]
55. Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom. Feher M; Vega-Hernandez G; Mocevic E; Buysse B; Myland M; Power GS; Nystrup Husemoen LL; Kim J; Witte DR Diabetes Ther; 2017 Apr; 8(2):417-431. PubMed ID: 28281244 [TBL] [Abstract][Full Text] [Related]
56. Semaglutide for the Treatment of Type 2 Diabetes Mellitus. Miles KE; Kerr JL J Pharm Technol; 2018 Dec; 34(6):281-289. PubMed ID: 34861016 [No Abstract] [Full Text] [Related]
57. Impact of Liraglutide to Semaglutide Conversion on Glycemic Control and Cost Savings at a Veterans Affairs Medical Center. Hardin M; Adanse F; Schexnayder C; Malveaux J; Agbahiwe S Fed Pract; 2023 Dec; 40(Suppl 6):S24-S30. PubMed ID: 38812588 [TBL] [Abstract][Full Text] [Related]
58. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224 [TBL] [Abstract][Full Text] [Related]
59. Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review. Robinson S; Boye KS; Mody R; Strizek AA; Konig M; Malik RE; Kennedy-Martin T Diabetes Ther; 2020 Jul; 11(7):1437-1466. PubMed ID: 32524494 [TBL] [Abstract][Full Text] [Related]
60. Real-World Hemoglobin A1c Changes, Prescribing Provider Types, and Medication Dose Among Patients with Type 2 Diabetes Mellitus Initiating Treatment with Oral Semaglutide. Frazer M; Swift C; Gronroos NN; Sargent A; Leszko M; Buysman E; Alvarez S; Dunn TJ; Noone J; Guevarra M Adv Ther; 2023 Nov; 40(11):5102-5114. PubMed ID: 37740832 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]